Loading...
Market
Supply disruption for any of the 15 negotiated drugs by 2026?
2
US•Medicare•Novo Nordisk•Ozempic•Wegovy•Rybelsus•Inflation Reduction Act•Trelegy Ellipta•Xtandi•Pomalyst•Ibrance•Ofev•Linzess•Calquence•Austedo•Breo Ellipta•Tradjenta•Xifaxan•Vraylar•Janumet•Janumet XR•Otezla
Resolution / Starting Odds
Yes • 50%
No • 50%
Reports from pharmaceutical companies or US healthcare agencies
Story
Medicare to Negotiate Prices of 15 Drugs Including Ozempic and Wegovy, New Prices Effective in 2027
Jan 17, 2025, 01:39 PM
The US government announced that Medicare will negotiate prices for an additional 15 drugs, including Novo Nordisk's blockbuster diabetes and weight loss medications Ozempic, Wegovy, and Rybelsus, with new prices to take effect in 2027. These drugs were selected in the second round of the Medicare Drug Price Negotiation Program under the Inflation Reduction Act. The negotiations aim to lower prescription costs for millions of seniors on Medicare, following the first round that delivered price reductions of 40% to 80%. Other drugs selected include Trelegy Ellipta, Xtandi, Pomalyst, Ibrance, Ofev, Linzess, Calquence, Austedo, Breo Ellipta, Tradjenta, Xifaxan, Vraylar, Janumet, Janumet XR, and Otezla. The initiative is expected to save the government more than $200 billion over a decade.
View original story
Similar markets
Increased demand • 25%
Supply chain disruptions • 25%
Regulatory changes • 25%
Manufacturing issues • 25%
More than 30 drugs • 25%
21-30 drugs • 25%
11-20 drugs • 25%
1-10 drugs • 25%
0-5 • 25%
16 or more • 25%
11-15 • 25%
6-10 • 25%
No • 50%
Yes • 50%
Semaglutide • 25%
Ozempic • 25%
Wegovy • 25%
Other • 25%
Ozempic • 25%
Wegovy • 25%
Janumet • 25%
Other • 25%
Ozempic • 25%
Janumet • 25%
Wegovy • 25%
Other • 25%
Cigna's Express Scripts • 25%
UnitedHealth Group's OptumRx • 25%
CVS Health's Caremark • 25%
None by end of 2025 • 25%